In the non-TNBC group, receiving neoadjuvant CT (P=0.001), being ≥70 years old (P<0.001), being postmenopausal (P=0.002), having a grade 2-3 disease (p=0.026), having the T3-4 disease (P<0.001), the having N2-3 disease (P<0.001), the presence of ECE (P<0.001), the presence of LVI (P<0.001), the presence of metastasis (P<0.001), the presence of brain (P<0.001) and visceral (P=0.014) metastasis and the presence of local regional recurrence (P=0.021) were found to have a negative effect on OS (Table 4). No effect on DFS was found while f a c t o r s l i ke being ≥70 years of age (P=0.05), having t he T3-4 disease (P=0.040), the presence of PNI (P=0.022), the presence of metastasis (P<0.001), and the presence of brain metastasis (P=0.049) had a negative effect on OS in univariate analysis in the TNBC group (Table 4). Receiving neoadjuvant CT (P=0.017), having the N2-3 disease (P=0.026), and the presence of ECE (P=0.049) had a negative effect on DFS. 2 Triple negative breast cancer (TNBC) consists of subgroups in which estrogen receptor (ER) and progesterone receptor (PR) stain less than 20 (P=0.014), having the T3-4 disease (P<0.001), having the N2-3 disease (P<0.001), the presence of ECE (P<0.001), the presence of PNI (P=0.014), the presence of LVI (P<0.001), the presence of metastasis (P<0.001), the presence of brain (P<0.001) and visceral (P=0.011) metastasis and the presence of local regional recurrence (P=0.004) were found to have a negative effect on OS in univariate analyses. 1 Breast cancer is a heterogeneous disease and is divided into 4 molecular groups: Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER-2) positive and triple negative subtypes according to hormone receptor status. Since hormonal treatment cannot be used in this group, individualization of treatments gains importance by knowing the prognostic factors.īreast cancer (BC) is the most common type of cancer in women in the world, and it is the 2 nd most common cause of cancer-related deaths. In the TNBC group, being ≥70 years of age (p=0.05), having T3-4 disease (p=0.040), presence of PNI (p=0.022), presence of metastasis (p<0.001), presence of brain metastasis (p=0.049) had a negative effect on OS in univariate analysis.Ĭonclusion: Shorter OS and DFS were found in the TNBC group similar to previous studies. Brain metastasis was observed more frequently in the TNBC group. It was not statistically significant as well as local recurrence was higher in the TNBC group. Disease-free survival (DFS) was median 29.7 months in the TNBC group and 52.37 months in the non-TNBC group. Results: 110(11.1%) of 992 patients were triple negative. Survival rates were evaluated using Kaplan Meirer method. Clinicopathological and treatment parameters of both groups were compared. Methods: The patients were divided into two groups as TNBC and non-TNBC. Determining the prognostic factors and parameters affecting survival in the TNBC group were aimed with this retrospective study. Background: Triple negative breast cancer (TNBC) is the most aggressive and worst prognosis group among breast cancer molecular subtypes.
0 Comments
Leave a Reply. |